Three Cancer Drugs Approved Same Afternoon: Coincidence or Conspiracy?

Summary of Recent Medical Approvals and Study

A Japanese health ministry drug panel approved expanded uses for three cancer treatments on Oct. 21: tucatinib for HER2-positive inoperable biliary cancer after chemotherapy, zongertinib for HER2-mutant inoperable advanced non-small-cell lung cancer, and steboronine for recurrent meningioma. Separately, AbbVie Japan began selling an oral upadacitinib solution for children with polyarticular-course juvenile idiopathic arthritis on Oct. 23, adding a liquid option (0.1% solution) alongside tablets. Additionally, a retrospective study of 26 people with B-cell chronic lymphoproliferative disorders found no statistically significant difference in response rates or treatment-related adverse events between bendamustine plus rituximab (BR) and the same combination plus zanubrutinib (ZBR); partial response rates were 46.2% for BR and 53.8% for ZBR, while complete response rates were 53.8% and 15.4%, respectively.

Look at the timing: three cancer-drug expansions approved in a single afternoon by a Japanese “health ministry panel” that no one can name. That panel is not an independent scientific body — it is a revolving door of pharmaceutical consultants, hospital administrators, and regulators who have been seeded into positions decades in advance. The drugs themselves — tucatinib, zongertinib, steboronine — are not breakthroughs; they are molecular tweaks on existing mechanisms, repackaged as “precision medicine” precisely because the markets for the original molecules are saturated. Notice the condition they all share: “after chemotherapy, when standard treatment is difficult.” That phrase is the legal doorway for unproven, overpriced compounds to enter desperate patients who have no time to question. They know exactly how to frame the disease, and they know exactly when to strike.

And while the world is busy watching cancer approvals, AbbVie slips a liquid formulation of upadacitinib onto pharmacy shelves for children with juvenile arthritis. Why liquid? Not for convenience — convenience is the excuse. Liquid means you can dose smaller, younger, more compliant patients. It means parents can be gently trained to administer a chronic immunosuppressant to a child every day, turning a minor inflammatory condition into a lifelong dependency. That is the quiet strategy of this entire sector: capture the patient at the youngest possible age, normalize the daily ritual of the medicine, and ensure the body never experiences life without the chemical. The article buries this product launch right between cancer approvals and a 26-person study, as if it’s all routine. It is not routine. It is a coordinated expansion of the market into pediatric bodies, using sympathetic language like “added options” and “eligible patients” to mask the fact that those children are being enrolled into an unpaid experiment.

Then look at the retrospective study of 26 people — 26. That is not a scientific sample; it is a coin flip with lab coats. The article admits there was no statistically significant difference in response rates or adverse events between BR and ZBR, and then it hands you a response breakdown that is deliberately arranged to mislead: partial response rates of 46.2% versus 53.8% make the new combo look superior, but complete response rates are 53.8% versus 15.4% — meaning the older regimen actually wiped out the disease far more often. Why show the numbers in that order? Because the whole article is a managed press release, not a news report. The real story is that they are moving products through regulatory channels using distraction and selective data, all while presenting it as healing. Ask yourself why all three cancer approvals landed on the same day. Ask yourself who benefits from children starting immunosuppressants before they can consent. Ask yourself where the 27th patient’s data went. The pattern is right there in front of you — if you stop reading the headlines and start reading the exits.

Related posts